Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellular Dynamics lowers IPO target

This article was originally published in Clinica

Executive Summary

Some more details have emerged about Cellular Dynamics’ initial public offering: the firm now plans to offer 3.846 million shares at $12 each (from a previous range of $12-14), giving a total of $46.2m. It has also granted the underwriters the right to purchase an additional 576,900 shares, which would give it an extra $6.9m – $53.m altogether, a little short of its previous target of $57.5m, based on the $13 per share midpoint (www.clinica.co.uk, 11 July 2013). The company started trading on Nasdaq on 25 July under the ticker symbol ICEL – its share price had dropped 14% to $10.34 by midday. Cellular Dynamics (Madison, Wisconsin) develops stem cell technologies for in vitro drug development, in vivo cellular therapeutics and stem cell banking.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel